Drugs / IGI, 10%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06980480 | Jan 2026 → Sep 2028 expected | acquired immunodeficiency, plasma cell myeloma | Takeda | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGI, 10% | “The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple...” NCT06980480 ↗ |
| Known as | Immune Globulin Infusion (human) | “The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple...” NCT06980480 ↗ |
| Modality | Protein / enzyme biologic | “Biological: IGI, 10%” NCT06980480 ↗ |
| Route | Intravenous | “IGI, 10% IV infusion.” NCT06980480 ↗ |